| Detected | Trial | Change |
|---|---|---|
| 2026-06-09 | NCT04895722 Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments… |
Trial arms changed: 5 -> 7 |
| 2026-05-28 | NCT04938817 Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With… |
overall status: "Recruiting" → "Active Not Recruiting" |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2 | |||
| NCT04895722 | Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments… | Colorectal Cancer | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT04165070 | KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or… | Carcinoma, Non-Small-Cell Lung | Recruiting |
| NCT05319730 | A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in… | Esophageal Squamous Cell Carcinoma | Recruiting |
| NCT04626518 | Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With… | Carcinoma, Renal Cell | Active, Not Recruiting |
| NCT04938817 | Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With… | Small Cell Lung Carcinoma | Active, Not Recruiting |